Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III
Comparison between two autograf therapeutic strategies in high risk patients Ramdomised
comparison between maintenance treatment with or not interferon alpha 2 a
Interventional
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
overall survival
time to death
Norbert IFRAH, Pr
Principal Investigator
Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
GOELAL02
NCT00483132
September 1994
April 2002
Name | Location |
---|